No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CN Stock MarketDetailed Quotes
300676 BGI Genomics
- 34.18
- -0.51-1.47%
Market Closed Jul 24 15:00 CST
14.21BMarket Cap221.95P/E (TTM)
34.89High34.01Low12.94KlotVolume34.78Open34.69Pre Close44.49MTurnover0.31%Turnover Ratio153.27P/E (Static)415.82MShares61.0952wk High1.43P/B14.11BFloat Cap32.9052wk Low41.63Limit Up412.84MShs Float259.49Historical High27.75Limit Down2.54%Amplitude13.87Historical Low0.10Dividend TTM34.38Avg Price6.04KlotAsk0.29%Div YieldTTM100Lot Size6.28KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
BGI Genomics Opens Lab in Kazakhstan
Is BGI Genomics Co., Ltd.'s (SZSE:300676) Recent Price Movement Underpinned By Its Weak Fundamentals?
BGI Genomics (300676.SZ) plans to distribute 1 yuan per 10 shares, with ex-dividend date on July 4th.
BGI Genomics (300676.SZ) announced that the annual equity distribution for 2023 is planned to be 1 yuan RMB cash (tax included) per 10 shares for all shareholders. The ex-right and ex-dividend date is July 4, 2024.
Shareholders in BGI Genomics (SZSE:300676) Are in the Red If They Invested Three Years Ago
Huada Gene (300676.SZ): BRCA1/2 gene mutation detection kit (combined with probe-anchored polymerization sequencing) registration terminated
Huada Gene (300676.SZ) announced that Huada Biotechnology (Wuhan) Co., Ltd., a wholly-owned subsidiary of the company (simplified...
Ronglian Technology (002642.SZ): The company participated in the construction of BGI related projects in the early stages
Gelonghui, May 17 | Ronglian Technology (002642.SZ) said on the investor interactive platform that as a professional digital service provider, the company has been deeply involved in the biomedical industry for more than ten years, focusing on the deep integration and innovative application of biotechnology and information technology, and has the ability to integrate internal and external resources and technical advantages to provide customers with specialized solutions. It mainly provides information technology products and services to clinical hospitals, scientific research institutions, biomedical companies and institutions of higher learning. The company participated in the construction of BGI Genomics related projects in the early stages.
Comments
BGI Genomics' low ROE and net income growth are worrisome. Despite high reinvestment, the low ROE indicates that it's not benefiting investors and is hampering earnings growth. Caution is advised due to these factors.
Are BGI Genomics Co., Ltd.'s (SZSE:300676) Mixed Financials Driving The Negative Sentiment?
BGI, MGI, Complete Genomics, Wuxi Apptec, and any subsidiary are included.
Last Friday, WuXi AppTec's shares tumble by 20% in Hong Kong and fall by a 10% limit-down in mainland China.
Other CRO stocks including Medicilon are also falling.
$WUXI BIO(02269.HK$ $WUXI APPTEC(02359.HK$ $BGI Genomics(300676.SZ$ $MGI Tech Co., Ltd.(688114.SH$ $Shanghai Medicilon Inc.(688202.SH$ $Novo-Nordisk A/S(NVO.US$ $Hang Seng H-Share Index ETF(02828.HK$
Last Friday, WuXi AppTec's shares tumble by 20% in Hong Kong and fall by a 10% limit-down in mainland China.
Other CRO stocks including Medicilon are also falling.
$WUXI BIO(02269.HK$ $WUXI APPTEC(02359.HK$ $BGI Genomics(300676.SZ$ $MGI Tech Co., Ltd.(688114.SH$ $Shanghai Medicilon Inc.(688202.SH$ $Novo-Nordisk A/S(NVO.US$ $Hang Seng H-Share Index ETF(02828.HK$
2
Despite a significant drop in BGI Genomics' EPS and share price, the market still sees a promising future, as indicated by its high P/E ratio. Investors should monitor the company's fundamentals and be vigilant for warning signs.
Investors currently view BGI Genomics as an underperforming company, largely influenced by its poor revenue growth over the past years. Its P/S ratio may tumble further if the company fails to improve its revenue growth, leading to further investor disappointment.
BGI Genomics' low ROE and limited earnings growth, despite high profit retention, raise concerns about its financial performance and efficient use of equity capital and profits. The current price momentum may not be sustainable.
Read more
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
%Chg